Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than forty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences companies which are developing hundreds of products to treat major underserved medical needs representing huge markets in the nearly two trillion dollar healthcare sector.

Brook was the founding President and then Chairman of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of eight companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nano...